INTELLIA THERAPEUTICS INC (NTLA)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for NTLA
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| NTLA | Board Member | 64 | ["Chief operating officer at Volnay Therapeutics","Chief operating officer for Takeda Research and Development","Global head of medical sciences and development operations at Takeda","Worked at Johnson & Johnson in multiple roles including vice president","Experience with Bristol-Myers Squibb and Novartis","NACD Directorship Certification","Leadership experience in pharmaceutical industry"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Dr. Keresty served on the audit committee throughout 2025, on the nominating and corporate governance committee throughout 2025, and on the science and technology committee throughout 2025. Our board of directors has determined that Dr. Keresty is independent for audit committee purposes as that term is defined in the applicable rules of the SEC and Nasdaq.